Corporate
DURHAM, North Carolina – Quantoom Biosciences S.A. (“Quantoom”), part of Univercells S.A., focused on mRNA production technologies for vaccines and…
Quantoom Biosciences S.A. (“Quantoom”), part of Univercells S.A. is proud to announce its significant collaboration with the Institute of Technology…
The Ntensify™ Midi System Sets the Stage for Equitable Vaccine Access Quantoom Biosciences S.A. (“Quantoom”), a Univercells company, proudly announces…
Quantoom Biosciences (‘Quantoom’) is thrilled to announce a new collaboration with Stevanato Group, a leading global provider of drug containment and…
Univercells S.A. (Univercells) today announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented…
Quantoom Biosciences S.A. (“Quantoom”), a biotech with the mission to improve access to essential medicines and autonomy in bioproduction through…
Univercells S.A. introduces its latest affiliate, Quantoom Biosciences S.A., a biotech with the mission to improve access to essential medicines…
